3.92

4.16% -0.17

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$4.09

Offen:

$4.16

24-Stunden-Volumen:

1.41M

Relative Volume:

0.61

Marktkapitalisierung:

$656.14M

Einnahmen:

$25.55M

Nettoeinkommen (Verlust:

$-341.97M

KGV:

-1.40

EPS:

-2.8

Netto-Cashflow:

$-304.44M

1W Leistung:

-2.00%

1M Leistung:

-15.88%

6M Leistung:

-47.17%

1J Leistung:

-62.60%

1-Tages-Spanne:

$3.92

$4.24

1-Wochen-Bereich:

$3.85

$4.24

52-Wochen-Spanne:

$3.50

$11.02

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

617-370-8837

Adresse

399 BINNEY STREET, CAMBRIDGE

Mitarbeiter

294

Twitter

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Vergleichen Sie RLAY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	3.92	656.14M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

Feb 20, 2025

Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Feb 20, 2025

Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 20, 2025

Feb 19, 2025

The Potential Rise in the Price of Relay Therapeutics Inc (RLAY) following insiders activity - Knox Daily

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian

Feb 19, 2025

Feb 16, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 Shares - MarketBeat

Feb 14, 2025

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of Stock - MarketBeat

Feb 14, 2025

Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock By Investing.com - Investing.com Australia

Feb 14, 2025

Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha

Feb 14, 2025

Feb 13, 2025

Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat

Feb 13, 2025

Feb 11, 2025

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down – Should You Sell? - Defense World

Feb 11, 2025

Q2 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Feb 10, 2025

Quarterly Metrics: Quick and Current Ratios for Relay Therapeutics Inc (RLAY) - The Dwinnex

Feb 10, 2025

Feb 08, 2025

Brokers Issue Forecasts for RLAY Q1 Earnings - Defense World

Feb 08, 2025

Feb 07, 2025

RLAY’s Market Whiplash: 9.47% YTD Rise, -1.31% Plunge in 30 Days - The InvestChronicle

Feb 07, 2025

Analysts Set Expectations for RLAY Q1 Earnings - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News

Feb 06, 2025

Feb 05, 2025

BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com

Feb 05, 2025

Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily

Feb 05, 2025

SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Feb 05, 2025

Feb 04, 2025

How should investors view Relay Therapeutics Inc (RLAY)? - US Post News

Feb 04, 2025

Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat

Feb 04, 2025

Feb 03, 2025

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat

Feb 03, 2025

Jan 31, 2025

Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com

Jan 31, 2025

Jan 30, 2025